

# Manuel Salto-Tellez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1718329/publications.pdf>

Version: 2024-02-01

123  
papers

8,041  
citations

109137

35  
h-index

58464

82  
g-index

127  
all docs

127  
docs citations

127  
times ranked

15375  
citing authors

#	ARTICLE	IF	CITATIONS
1	Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP). <i>Gut</i> , 2022, 71, 854-863.	6.1	57
2	Identification of a prognostic signature in colorectal cancer using combinatorial algorithm-driven analysis. <i>Journal of Pathology: Clinical Research</i> , 2022, , .	1.3	1
3	Potential quality pitfalls of digitalized whole slide image of breast pathology in routine practice. <i>Modern Pathology</i> , 2022, 35, 903-910.	2.9	8
4	Swarm learning for decentralized artificial intelligence in cancer histopathology. <i>Nature Medicine</i> , 2022, 28, 1232-1239.	15.2	77
5	General Roadmap and Core Steps for the Development of AI Tools in Digital Pathology. <i>Diagnostics</i> , 2022, 12, 1272.	1.3	4
6	Digital pathology and artificial intelligence will be key to supporting clinical and academic cellular pathology through COVID-19 and future crises: the PathLAKE consortium perspective. <i>Journal of Clinical Pathology</i> , 2021, 74, 443-447.	1.0	49
7	Identifying mismatch repair-deficient colon cancer: near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series. <i>Histopathology</i> , 2021, 78, 401-413.	1.6	55
8	Diagnosis of digestive system tumours. <i>International Journal of Cancer</i> , 2021, 148, 1040-1050.	2.3	36
9	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 288-300.	3.2	13
10	QuPath: The global impact of an open source digital pathology system. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 852-859.	1.9	49
11	Evolutionary genetic algorithm identifies <i>IL2RB</i> as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. <i>NAR Genomics and Bioinformatics</i> , 2021, 3, lqab016.	1.5	10
12	Colonic epithelial cathelicidin ( <i>LL-37</i> ) expression intensity is associated with progression of colorectal cancer and presence of <i>CD8<sup>+</sup></i> T cell infiltrate. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 495-506.	1.3	8
13	The clinical and molecular significance associated with STING signaling in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 81.	2.3	21
14	A Means of Assessing Deep Learning-Based Detection of ICOS Protein Expression in Colon Cancer. <i>Cancers</i> , 2021, 13, 3825.	1.7	17
15	Orthogonal <i>MET</i> analysis in a population-representative stage III colon cancer cohort: prognostic and potential therapeutic implications. <i>Molecular Oncology</i> , 2021, 15, 3317-3328.	2.1	3
16	HistoClean: Open-source software for histological image pre-processing and augmentation to improve development of robust convolutional neural networks. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4840-4853.	1.9	5
17	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. <i>Cancer Discovery</i> , 2021, 11, 1212-1227.	7.7	139
18	PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics. <i>Cancers</i> , 2021, 13, 29.	1.7	11

#	ARTICLE	IF	CITATIONS
19	Comparison of Molecular Assays for HPV Testing in Oropharyngeal Squamous Cell Carcinomas: A Population-Based Study in Northern Ireland. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 31-38.	1.1	14
20	Systematic evaluation of PAXgene <sup>®</sup> tissue fixation for the histopathological and molecular study of lung cancer. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 40-54.	1.3	8
21	Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study. <i>Cancer Causes and Control</i> , 2020, 31, 1-11.	0.8	16
22	Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. <i>British Journal of Cancer</i> , 2020, 123, 1280-1288.	2.9	45
23	A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. <i>Molecular Oncology</i> , 2020, 14, 2384-2402.	2.1	71
24	Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. <i>Cancers</i> , 2020, 12, 1114.	1.7	34
25	The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. <i>BMC Cancer</i> , 2020, 20, 500.	1.1	20
26	Low <sup>^</sup> contact and high <sup>^</sup> interconnectivity pathology (LC&HI Path): post <sup>^</sup> COVID19 <sup>^</sup> pandemic practice of pathology. <i>Histopathology</i> , 2020, 77, 518-524.	1.6	9
27	Gastrointestinal tissue <sup>^</sup> based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. <i>Histopathology</i> , 2020, 77, 340-350.	1.6	26
28	NUQA: Estimating Cancer Spatial and Temporal Heterogeneity and Evolution through Alignment-Free Methods. <i>Molecular Biology and Evolution</i> , 2019, 36, 2883-2889.	3.5	1
29	Defining the molecular evolution of extrauterine high grade serous carcinoma. <i>Gynecologic Oncology</i> , 2019, 155, 305-317.	0.6	17
30	Training and accreditation standards for pathologists undertaking clinical trial work. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 100-107.	1.3	10
31	Cancer taxonomy: pathology beyond pathology. <i>European Journal of Cancer</i> , 2019, 115, 57-60.	1.3	10
32	Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach. <i>British Journal of Cancer</i> , 2019, 120, 827-833.	2.9	51
33	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. <i>Gut</i> , 2019, 68, 1918-1927.	6.1	18
34	Invited review <sup>^</sup> next-generation sequencing: a modern tool in cytopathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 3-11.	1.4	31
35	High PTGS2 expression in post <sup>^</sup> neoadjuvant chemotherapy <sup>^</sup> treated oesophageal adenocarcinoma is associated with improved survival: a population <sup>^</sup> based cohort study. <i>Histopathology</i> , 2019, 74, 587-596.	1.6	1
36	Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities. <i>Journal of Thoracic Oncology</i> , 2019, 14, 45-53.	0.5	42

#	ARTICLE	IF	CITATIONS
37	Artificial intelligence—the third revolution in pathology. <i>Histopathology</i> , 2019, 74, 372-376.	1.6	107
38	Practical guide for the comparison of two next-generation sequencing systems for solid tumour analysis in a universal healthcare system. <i>Journal of Clinical Pathology</i> , 2019, 72, 225-231.	1.0	7
39	A digital pathology demonstration of an "immune hot" ICOS+/CD45RO+ immunophenotype and the impact on survival in patients with esophageal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 4062-4062.	0.8	0
40	Abstract LB-088: Exploratory multiplex tissue image analysis of the impact of heterogeneity in the microenvironment of primary colorectal cancer on apoptosis markers in patients. , 2019, , .		0
41	Abstract 2787: Artificial intelligence approach identifies IL2RB as a common prognostic and potential predictive biomarker associated with immune checkpoints in colorectal cancer. , 2019, , .		0
42	Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis. <i>Histopathology</i> , 2018, 73, 327-338.	1.6	63
43	HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee. <i>Journal of Clinical Pathology</i> , 2018, 71, 388-394.	1.0	14
44	More Than a Decade of Molecular Diagnostic Cytopathology Leading Diagnostic and Therapeutic Decision-Making. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, , .	1.2	6
45	Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer. <i>Laboratory Investigation</i> , 2018, 98, 15-26.	1.7	81
46	More Than a Decade of Molecular Diagnostic Cytopathology Leading Diagnostic and Therapeutic Decision-Making. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 443-445.	1.2	26
47	A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 103-113.	1.3	20
48	Time for change: a new training programme for morpho-molecular pathologists?. <i>Journal of Clinical Pathology</i> , 2018, 71, 285-290.	1.0	21
49	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. <i>Journal of Oncology</i> , 2018, 2018, 1-14.	0.6	44
50	Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression. <i>JCO Precision Oncology</i> , 2018, 2, 1-17.	1.5	3
51	Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 18518-18528.	0.8	13
52	Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study. <i>Oncotarget</i> , 2018, 9, 34347-34356.	0.8	7
53	Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort study. <i>Oncotarget</i> , 2018, 9, 35300-35312.	0.8	6
54	Abstract 1555: A gene signature associated with PTEN activation defines good outcomes in intermediate-risk prostate cancer cases. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 4049: Assessment of immune biomarkers by digital pathological analysis across a large colorectal cancer patient cohort predicts patient outcome and may provide a clinically relevant therapeutic index for immunotherapeutic treatment stratification. , 2018, , .		0
56	Abstract 3142: Tumor-infiltrating lymphocytes and CD4/FOXP3 ratios reliably predict survival using digital image analysis. , 2018, , .		0
57	Abstract B035: Radio-resistance of PTEN-deficient prostate tumors is enhanced by treatment-induced chemokine signaling and is associated with biochemical recurrence and development of metastasis. , 2018, , .		0
58	Tissue-based next generation sequencing: application in a universal healthcare system. British Journal of Cancer, 2017, 116, 553-560.	2.9	38
59	BCL-2 system analysis identifies high-risk colorectal cancer patients. Gut, 2017, 66, 2141-2148.	6.1	40
60	Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study. Clinical and Translational Gastroenterology, 2017, 8, e91.	1.3	56
61	Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Modern Pathology, 2017, 30, 1287-1298.	2.9	23
62	Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study. British Journal of Cancer, 2017, 116, 1652-1659.	2.9	37
63	Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 2017, 117, 203-209.	2.9	38
64	Standardising RNA profiling based biomarker application in cancerâ€”The need for robust control of technical variables. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 258-272.	3.3	16
65	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 2017, 14, 562-576.	12.5	150
66	QuPath: Open source software for digital pathology image analysis. Scientific Reports, 2017, 7, 16878.	1.6	3,854
67	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw199.	3.0	338
68	A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. Clinical Cancer Research, 2017, 23, 1200-1212.	3.2	21
69	Morphomolecular pathology: setting the framework for a new generation of pathologists. British Journal of Cancer, 2017, 117, 1581-1582.	2.9	16
70	Rare cancers: the greatest inequality in cancer research and oncology treatment. British Journal of Cancer, 2017, 117, 1255-1257.	2.9	8
71	RNAscope <i>in situ</i> hybridization confirms mRNA integrity in formalin-fixed, paraffin-embedded cancer tissue samples. Oncotarget, 2017, 8, 93392-93403.	0.8	41
72	PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, 4023-4023.	0.8	1

#	ARTICLE	IF	CITATIONS
73	samExploreR: exploring reproducibility and robustness of RNA-seq results based on SAM files. <i>Bioinformatics</i> , 2016, 32, 3345-3347.	1.8	11
74	p16 as a prognostic indicator in ovarian/tubal high-grade serous carcinoma. <i>Histopathology</i> , 2016, 68, 615-618.	1.6	8
75	Validation of immunocytochemistry as a morphomolecular technique. <i>Cancer Cytopathology</i> , 2016, 124, 540-545.	1.4	14
76	Quantification of HER2 heterogeneity in breast cancer—implications for identification of sub-dominant clones for personalised treatment. <i>Scientific Reports</i> , 2016, 6, 23383.	1.6	38
77	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 582-591.	1.6	35
78	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4095-4104.	3.2	135
79	Building a “Repository of Science”™: The importance of integrating biobanks within molecular pathology programmes. <i>European Journal of Cancer</i> , 2016, 67, 191-199.	1.3	31
80	Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. <i>Cancer</i> , 2016, 122, 664-673.	2.0	5
81	PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry. <i>Human Pathology</i> , 2016, 47, 95-103.	1.1	17
82	EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 230-242.	3.2	97
83	EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INNOVATION trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4133-TPS4133.	0.8	2
84	GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4154-TPS4154.	0.8	9
85	PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. <i>Oncotarget</i> , 2016, 7, 7885-7898.	0.8	33
86	Gelsolin-mediated activation of PI3K/Akt pathway is crucial for hepatocyte growth factor-induced cell scattering in gastric carcinoma. <i>Oncotarget</i> , 2016, 7, 25391-25407.	0.8	13
87	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 36632-36644.	0.8	15
88	Caspase modelling to predict personalised risk in stage III colorectal cancer (CRC) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11592-11592.	0.8	0
89	A systems model of BCL-2 dependent apoptosis to predict stage II CRC patients benefiting from adjuvant chemotherapy and as a prognostic tool for stage III CRC patients with increased risk of recurrence.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3584-3584.	0.8	1
90	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 217.	1.8	36

#	ARTICLE	IF	CITATIONS
91	Automated tumor analysis for molecular profiling in lung cancer. <i>Oncotarget</i> , 2015, 6, 27938-27952.	0.8	43
92	RE: Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv055-djv055.	3.0	0
93	Integrated molecular pathology: the Belfast model. <i>Drug Discovery Today</i> , 2015, 20, 1451-1454.	3.2	6
94	PICan: An integromics framework for dynamic cancer biomarker discovery. <i>Molecular Oncology</i> , 2015, 9, 1234-1240.	2.1	15
95	Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics. <i>Journal of Clinical Pathology</i> , 2015, 68, 766-770.	1.0	37
96	Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. <i>Modern Pathology</i> , 2015, 28, 428-436.	2.9	27
97	MERCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3632-TPS3632.	0.8	3
98	The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers. <i>Oncotarget</i> , 2015, 6, 12763-12773.	0.8	14
99	Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. <i>Oncotarget</i> , 2015, 6, 20863-20874.	0.8	41
100	Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention. <i>Oncotarget</i> , 2015, 6, 43244-43254.	0.8	8
101	Molecular classification of the invasive front in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3573-3573.	0.8	0
102	Abstract 4792: Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with clinical utility. , 2015, , .		0
103	Abstract 4018: The role of c-MET/HGF signaling as a critical mediator of an invasive and resistant phenotype in colorectal cancer. , 2015, , .		1
104	Sphingosine Kinase 1 Promotes Malignant Progression in Colon Cancer and Independently Predicts Survival of Patients With Colon Cancer by Competing Risk Approach in South Asian Population. <i>Clinical and Translational Gastroenterology</i> , 2014, 5, e51.	1.3	34
105	Identification and Validation of an Anthracycline/Cyclophosphamide-Based Chemotherapy Response Assay in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt335.	3.0	91
106	The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. <i>Histopathology</i> , 2014, 65, 340-352.	1.6	59
107	Next-generation sequencing: a change of paradigm in molecular diagnostic validation. <i>Journal of Pathology</i> , 2014, 234, 5-10.	2.1	68
108	AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 164-175.	3.2	95

#	ARTICLE	IF	CITATIONS
109	BRCA1 Deficiency Exacerbates Estrogen-Induced DNA Damage and Genomic Instability. <i>Cancer Research</i> , 2014, 74, 2773-2784.	0.4	94
110	Digital pathology and image analysis in tissue biomarker research. <i>Methods</i> , 2014, 70, 59-73.	1.9	162
111	Molecular pathology – The value of an integrative approach. <i>Molecular Oncology</i> , 2014, 8, 1163-1168.	2.1	32
112	Identification of a BRCA1-mRNA Splicing Complex Required for Efficient DNA Repair and Maintenance of Genomic Stability. <i>Molecular Cell</i> , 2014, 54, 445-459.	4.5	146
113	Abstract 2079: EpHA2 is an essential driver of invasion and a novel target in KRAS mutant colorectal cancer. , 2014, , .		1
114	Association of a DNA damage response deficiency (DDR) assay and prognosis in early-stage esophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4015-4015.	0.8	3
115	The prognostic and therapeutic value of EpHA2 in early colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3581-3581.	0.8	0
116	Abstract 1905: Defining a therapeutic classification of breast cancer by actionable targets. , 2014, , .		0
117	Guidelines and considerations for conducting experiments using tissue microarrays. <i>Histopathology</i> , 2013, 62, 827-839.	1.6	57
118	Immunohistochemistry in the era of personalised medicine. <i>Journal of Clinical Pathology</i> , 2013, 66, 58-61.	1.0	40
119	MicroRNA-34c Inversely Couples the Biological Functions of the Runt-related Transcription Factor RUNX2 and the Tumor Suppressor p53 in Osteosarcoma. <i>Journal of Biological Chemistry</i> , 2013, 288, 21307-21319.	1.6	95
120	Identification and validation of an assay predictive of response and prognosis following anthracycline-based chemotherapy for early breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS11120-TPS11120.	0.8	0
121	Molecular Pathology in Contemporary Diagnostic Pathology Laboratory. <i>American Journal of Surgical Pathology</i> , 2010, 34, 115-117.	2.1	15
122	Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients. <i>Virus Research</i> , 2009, 145, 260-269.	1.1	85
123	Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast Cancer. <i>Modern Pathology</i> , 2003, 16, 79-85.	2.9	161